CoChat

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

Open access
McCrimmon, Rory J., Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Thielke, Desirée, Lingvay, Ildiko · 2020 · Diabetologia

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a subset of participants from the SUSTAIN 8 Phase IIIB, randomised double-blind trial who underwent whole-body dual-energy x-ray absorptiometry (DXA) scanning. Methods: Adults (age ≥18 years) with type 2 diabetes, HbA 1c 53–91 mmol/mol (7.0–10.5%), on a stable daily dose of metformin (≥1500 mg or maximum tolerated dose) and with an eGFR ≥60 ml min −1 [1.73 m] −2 were randomised 1:1 to semaglutide 1.0 mg once weekly and canagliflozin placebo once daily, or canagliflozin 300 mg once daily and semaglutide placebo once weekly. Body composition was assessed using whole-body DXA scans. The study participants and investigator remained blinded throughout the trial, and quality of DXA scans was evaluated in a blinded manner. Change from baseline to week 52 in total fat mass (kg) was the confirmatory efficacy endpoint. Results: A subset of 178 participants (semaglutide, n = 88; canagliflozin, n = 90) underwent DXA scanning at screening and were randomised into the substudy. Of these, 114 (semaglutide, n = 53; canagliflozin, n = 61) participants had observed end-of-treatment data included in the confirmatory efficacy analysis. Of the 178 participants in the substudy, numerical improvements in body composition (including fat mass, lean mass and visceral fat mass) were observed after 52 weeks with both treatments. Total fat mass (baseline 33.2 kg) was reduced by 3.4 kg and 2.6 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: –0.79 [95% CI −2.10, 0.51]). Although total lean mass (baseline 51.3 kg) was also reduced by 2.3 kg and 1.5 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: −0.78 [−1.61, 0.04]), the proportion of lean mass (baseline 59.4%) increased by 1.2%- and 1.1%-point, respectively (estimated treatment difference 0.14 [−0.89, 1.17]). Changes in visceral fat mass and overall changes in body composition (assessed by the fat to lean mass ratio) were comparable between the two treatment groups. Conclusions/interpretation: In individuals with uncontrolled type 2 diabetes on stable-dose metformin therapy, the changes in body composition with semaglutide and canagliflozin were not significantly different. Although numerical improvements in body composition were observed following treatment in both treatment arms, the specific impact of both treatments on body composition in the absence of a placebo arm is speculative at this stage. Trial registration: ClinicalTrials.gov NCT03136484. Funding: This trial was supported by Novo Nordisk A/S, Denmark.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-019-05065-8

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Graphical illustration of the closed testing procedure. The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA1c non-inferiority test. The local significance level (αlocal) will be reallocated if a hypothesis is confirmed according to the weight given by the directed edges between nodes (hypotheses). The total fat-mass superiority test will receive the overall significance of α = 0.05 (two-sided) if, and only if, both HbA1c and body weight superiority are confirmed at their respective local significance levels
Fig. 1 Graphical illustration of the closed testing procedure. The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA1c non-inferiority test. The local significance level (αlocal) will be reallocated if a hypothesis is confirmed according to the weight given by the directed edges between nodes (hypotheses). The total fat-mass superiority test will receive the overall significance of α = 0.05 (two-sided) if, and only if, both HbA1c and body weight superiority are confirmed at their respective local significance levelsCC BY · PubMed Central
Fig. 2 Participant disposition. aParticipants could meet more than one exclusion criterion. b‘Not assigned’ includes individuals who withdrew consent before randomisation. cParticipants in the substudy were a subset of the overall SUSTAIN 8 trial population. dIn participants for whom data were outside the relevant observation period, only baseline participant data were included in the analysis, and the corresponding end-of-treatment data were multiple imputed. eThe in-trial analysis included all available post-baseline data. Missing data were multiple imputed
Fig. 2 Participant disposition. aParticipants could meet more than one exclusion criterion. b‘Not assigned’ includes individuals who withdrew consent before randomisation. cParticipants in the substudy were a subset of the overall SUSTAIN 8 trial population. dIn participants for whom data were outside the relevant observation period, only baseline participant data were included in the analysis, and the corresponding end-of-treatment data were multiple imputed. eThe in-trial analysis included all available post-baseline data. Missing data were multiple imputedCC BY · PubMed Central
Fig. 3 Body composition outcomes after 52 weeks of treatment. Change from baseline in total fat mass: kg (a) and % (b); total lean mass: kg (c) and % (d); visceral fat mass: kg (e) and % (f); ratio of total fat mass to total lean mass (g); and cumulative change in total fat mass (h). ‘On-treatment without rescue medication’ data ( n =114 [semaglutide, n = 53; canagliflozin, n = 61]). Missing data were multiple imputed using observed data from participants within the same group defined by randomised treatment, using a regression model including region as categorical effect and data from baseline as covariate. (a–g) Responses were analysed using an ANCOVA with treatment and region as fixed factors and baseline value as covariate. Regions were defined as North America (USA and Canada); Region Europe (UK, Ireland and Sweden); or International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil and India). Numbers on the bars may not match the numbers on the scale due to rounding. (h) The dashed line on the y-axis shows the 50th percentile, while the dashed line on the x-axis shows the reference value for no change
Fig. 3 Body composition outcomes after 52 weeks of treatment. Change from baseline in total fat mass: kg (a) and % (b); total lean mass: kg (c) and % (d); visceral fat mass: kg (e) and % (f); ratio of total fat mass to total lean mass (g); and cumulative change in total fat mass (h). ‘On-treatment without rescue medication’ data ( n =114 [semaglutide, n = 53; canagliflozin, n = 61]). Missing data were multiple imputed using observed data from participants within the same group defined by randomised treatment, using a regression model including region as categorical effect and data from baseline as covariate. (a–g) Responses were analysed using an ANCOVA with treatment and region as fixed factors and baseline value as covariate. Regions were defined as North America (USA and Canada); Region Europe (UK, Ireland and Sweden); or International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil and India). Numbers on the bars may not match the numbers on the scale due to rounding. (h) The dashed line on the y-axis shows the 50th percentile, while the dashed line on the x-axis shows the reference value for no changeCC BY · PubMed Central
Fig. 4 Correlation of absolute change in total fat mass (kg) with change in body weight (a), HbA1c (b), SBP (c) and DBP (d) after 52 weeks of treatment. Each point represents data (observed or imputed) from one participant. ‘On-treatment without rescue medication’ data for all randomised participants (n = 178 [semaglutide, n = 88; canagliflozin, n = 90]). Missing data were multiple imputed using data from participants within the same group defined by randomised treatment. Data are plotted for the first ten out of 500 imputations. DBP, diastolic BP; SBP, systolic BP
Fig. 4 Correlation of absolute change in total fat mass (kg) with change in body weight (a), HbA1c (b), SBP (c) and DBP (d) after 52 weeks of treatment. Each point represents data (observed or imputed) from one participant. ‘On-treatment without rescue medication’ data for all randomised participants (n = 178 [semaglutide, n = 88; canagliflozin, n = 90]). Missing data were multiple imputed using data from participants within the same group defined by randomised treatment. Data are plotted for the first ten out of 500 imputations. DBP, diastolic BP; SBP, systolic BPCC BY · PubMed Central
Fig. 5 Proportion of participants achieving weight loss ≥3%, 5%, 10% or 15% of body weight from baseline after 52 weeks of treatment with semaglutide 1.0 mg (a) and canagliflozin 300 mg (b) in SUSTAIN 8 (n = 788) and the SUSTAIN 8 substudy (n = 178). ‘On-treatment without rescue medication’ data. Missing data were multiple imputed using observed data from participants within the same group defined by randomised treatment, using a regression model including region and stratification factor as categorical effects and data from baseline and all previous visits as covariates. Regions were defined as North America (USA and Canada); Region Europe (UK, Ireland and Sweden); or International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil and India). This post hoc comparison of change in body weight within the substudy vs the primary study was performed in order to confirm that weight loss in participants undergoing a DXA scan in the substudy was representative of the weight loss in the primary study
Fig. 5 Proportion of participants achieving weight loss ≥3%, 5%, 10% or 15% of body weight from baseline after 52 weeks of treatment with semaglutide 1.0 mg (a) and canagliflozin 300 mg (b) in SUSTAIN 8 (n = 788) and the SUSTAIN 8 substudy (n = 178). ‘On-treatment without rescue medication’ data. Missing data were multiple imputed using observed data from participants within the same group defined by randomised treatment, using a regression model including region and stratification factor as categorical effects and data from baseline and all previous visits as covariates. Regions were defined as North America (USA and Canada); Region Europe (UK, Ireland and Sweden); or International Operations (Lebanon, Malaysia, Argentina, Mexico, Brazil and India). This post hoc comparison of change in body weight within the substudy vs the primary study was performed in order to confirm that weight loss in participants undergoing a DXA scan in the substudy was representative of the weight loss in the primary studyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

12 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. International Conference on Harmonisation–World Health Organization Guideline for Good Clinical Practice (1996) ICH harmonised tripartite guideline good clinical practice. Available from https://apps.who.int/medicinedocs/en/m/abstract/Js22154en/. Accessed 25 November 2019

Cited by

See all 184

Metadata

Authors
McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I.
Affiliations
  • University of Dundee (GB)
  • Novo Nordisk (Denmark) (DK)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
McCrimmon, Rory J.
Venue
Diabetologia
Published
2020-01-02
Volume
63
Issue
3
Pages
473-485
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2997634477
Cited by
184
References
48
Citations by year
2026: 56 · 2025: 61 · 2024: 30 · 2023: 20 · 2022: 7 · 2021: 6 · 2020: 3
FWCI
6.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, canagliflozin, type 2 diabetes, body composition, fat mass, lean body mass, visceral fat, GLP-1 receptor agonists, SGLT2 inhibitors, dual-energy X-ray absorptiometry, insulin resistance, cardiovascular risk, weight loss
MeSH terms
Canagliflozin, Semaglutide, Aged, Blood Glucose, Body Composition, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Routes, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Male, Metformin, Middle Aged, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. https://app.cochat.ai/papers/10.1007/s00125-019-05065-8
The paper
McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020). Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. https://doi.org/10.1007/s00125-019-05065-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.